Brainstorm Cell Therapeutics reported $-5475000 in Operating Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Biogen BIIB:US $ 610.7M 23.6M
Brainstorm Cell Therapeutics BCLI:US $ -5475000 737K
Cerulean Pharma CERU:US $ -8400450 1.14M
Cytokinetics CYTK:US $ -80.55M 58.85M
Gilead Sciences GILD:US $ 197M 743M
Halozyme Therapeutics HALO:US $ 75.67M 19.14M
Idera Pharmaceuticals IDRA:US $ -4.18M 0.06M